Who owns Eikon Therapeutics, Inc., from the filings themselves: stakes over 5% (Schedule 13D/G), the institutional managers reporting the stock each quarter (13F), and the funds holding it (N-PORT).
Investors crossing 5% ownership must disclose it. Schedule 13G filers certify the stake is passive; Schedule 13D is the general form for everyone else — founders, strategic holders, and activists alike. Each entry is the holder's most recent disclosure. Coverage begins with SEC's structured filings from December 18, 2024; a holder appears once they file or amend after that date.
FMR LLC: 9.2% · 4,993,906 shares — Abigail P. Johnson: 9.2% · 4,993,906 shares
Innovation Endeavors III LP: 5.0% · 2,723,226 shares — Innovation Endeavors III GP, LLC: 5.0% · 2,723,226 shares — Innovation Endeavors IV LP: 0.9% · 498,474 shares
5 more 5% stakes behind a free account
See every investor who has disclosed crossing 5% of Eikon Therapeutics, Inc..
Sign up freeEvery institutional manager whose latest 13F reports this stock, largest position first. "% of their portfolio" is the weight inside that manager's own book — how much conviction the position represents; "% of company" is how much of Eikon Therapeutics, Inc. they hold. Together these 135 managers report 72.56% of shares outstanding.
| Investor | Position value | Shares | % of their portfolio | % of company | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. | $66.1M | 4,676,289 | 0.00% | 8.63% | June 30, 2026 |
| FMR LLC | $65.2M | 4,994,254 | 0.00% | 9.22% | June 30, 2026 |
133 more institutional holders behind a free account
See every manager reporting Eikon Therapeutics, Inc., how much of the company they hold, and how big the position is inside their own portfolio.
Sign up freeFunds disclosing this stock in their monthly N-PORT portfolio, with the position's share of the fund's net assets. Together these 71 funds hold 15.40% of shares outstanding — counted inside the manager totals above, not on top of them, since a fund's shares also appear in its manager's 13F.
| Fund | Position value | % of net assets | % of company | As of |
|---|---|---|---|---|
| Fidelity Contrafund | $16.6M | 0.01% | 2.36% | June 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | $15.9M | 0.00% | 1.74% | June 30, 2026 |
69 more funds behind a free account
See every fund holding Eikon Therapeutics, Inc. and what share of its net assets the position represents.
Sign up freeLoading...
